NOVN Key Statistics, Chart & Performance
The current stock price of NOVN is 0.0941 USD. In the past month the price decreased by -77.43%. In the past year, price decreased by -96.77%.
NOVN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.84 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.97 | 499.41B | ||
| MRK | MERCK & CO. INC. | 12.57 | 274.81B | ||
| PFE | PFIZER INC | 7.99 | 145.30B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.81B | ||
| ZTS | ZOETIS INC | 20.04 | 56.00B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.81 | 23.26B | ||
| VTRS | VIATRIS INC | 5.45 | 14.64B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.63 | 11.75B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.92B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.57B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.13B |
Related stock screener links
About NOVN
Company Profile
Novan, Inc. is a medical dermatology company, which engages in the development and commercialization of therapeutic products for skin diseases. The company is headquartered in Durham, North Carolina and currently employs 89 full-time employees. The company went IPO on 2016-09-21. The firm is focused on developing and commercializing therapeutic products for skin diseases. The firm is engaged in developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a focus on molluscum contagiosum (molluscum). The firm's commercial portfolio includes six branded prescription drugs. The company actively promotes three medical dermatological products in the United States, such as Wynzora (calcipotriene and betamethasone dipropionate), Rhofade (oxymetazoline hydrochloride), and Minolira (minocycline hydrochloride). Wynzora is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis. Rhofade is an alpha1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema. Minolira is indicated to treat inflammatory lesions.
Company Info
NOVAN INC
4020 Stirrup Creek Drive, Suite 110
Durham NORTH CAROLINA 27703 US
CEO: Paula Brown Stafford
Employees: 89
Phone: 19194858080.0
NOVAN INC / NOVN FAQ
Can you describe the business of NOVAN INC?
Novan, Inc. is a medical dermatology company, which engages in the development and commercialization of therapeutic products for skin diseases. The company is headquartered in Durham, North Carolina and currently employs 89 full-time employees. The company went IPO on 2016-09-21. The firm is focused on developing and commercializing therapeutic products for skin diseases. The firm is engaged in developing SB206 (berdazimer gel, 10.3%) as a topical prescription gel for the treatment of viral skin infections, with a focus on molluscum contagiosum (molluscum). The firm's commercial portfolio includes six branded prescription drugs. The company actively promotes three medical dermatological products in the United States, such as Wynzora (calcipotriene and betamethasone dipropionate), Rhofade (oxymetazoline hydrochloride), and Minolira (minocycline hydrochloride). Wynzora is a combination of calcipotriene, a vitamin D analog, and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis. Rhofade is an alpha1A adrenoceptor agonist indicated for the topical treatment of persistent facial erythema. Minolira is indicated to treat inflammatory lesions.
What is the current price of NOVN stock?
The current stock price of NOVN is 0.0941 USD. The price decreased by -24.84% in the last trading session.
Does NOVAN INC pay dividends?
NOVN does not pay a dividend.
What is the ChartMill technical and fundamental rating of NOVN stock?
NOVN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does NOVAN INC belong to?
NOVAN INC (NOVN) operates in the Health Care sector and the Pharmaceuticals industry.
When is the next dividend date for NOVAN INC (NOVN)?
The next ex-dividend date for NOVAN INC (NOVN) is November 4, 2022.
Can you provide the number of employees for NOVAN INC?
NOVAN INC (NOVN) currently has 89 employees.
NOVN Technical Analysis
NOVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NOVN. NOVN has a bad profitability rating. Also its financial health evaluation is rather negative.
NOVN Financial Highlights
Over the last trailing twelve months NOVN reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS increased by 21.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NOVN Forecast & Estimates
7 analysts have analysed NOVN and the average price target is 15.81 USD. This implies a price increase of 16701.28% is expected in the next year compared to the current price of 0.0941.
For the next year, analysts expect an EPS growth of 78.75% and a revenue growth 19.34% for NOVN